Samsrita Labs Limited operates as a biopharmaceutical company in India. The company offers DNA, RNA, and chromosomal-based tests for oncology, pharmacogenomics, infectious diseases, genetic disorders, transplantation typing, and prenatal and pre-implantation genetic diagnostics; and quantitative/real-time polymerase chain reaction (qPCR), multiplex ligation-dependent probe amplification (MLPA), Sanger and Next Generation Sequencing (NGS), karyotype, and fluorescence in-situ hybridization analysis. It is also involved in the stem cell research and therapy, including regenerative medicine, bio-artificial organ scaffold development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology for the body organs of the liver, pancreas, neural, cardiac, vascular, renal, and orthopedic systems. In addition, company engages in new drug discovery, targeting therapeutic areas, such as Wilson's disease, non-alcoholic steatohepatitis, neuropathic pain, cardiova
| Current Price | ₹13.84 |
|---|---|
| Market Cap | ₹31 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | -3.5 |
| Return on Equity | -68.79% |
| Beta (1Y) | -0.16 |
Dr. Habeebbullal Life Sciences Ltd is trading at ₹13.84, with a market capitalisation of ₹31 Cr.
Dr. Habeebbullal Life Sciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Dr. Habeebbullal Life Sciences Ltd has a P/E of -3.5 and a return on equity of -68.79%.